Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapy

Galli M, Chatterjee M, Grasso M, Specchia G, Magen H, Einsele H, Celeghini I, Barbieri P, Paoletti D, Pace S, Sanderson RD, Rambaldi A, Nagler A (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Haematologica Ferrata Storti Foundation

Book Volume: 103

Pages Range: e469-e472

Journal Issue: 10

DOI: 10.3324/haematol.2017.182865

Involved external institutions

Universitätsklinikum Würzburg

Germany (DE) Azienda Ospedaliera S. Croce e Carle Cuneo

Italy (IT) Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari

Italy (IT) Leadiant Biosciences

Italy (IT) University of Alabama at Birmingham (UAB)

United States (USA) (US) ASST Papa Giovanni XXIII

Italy (IT) Chaim Sheba Medical Center at Tel HaShomer / המרכז הרפואי עש חיים שיבא – תל השומר‎‎

Israel (IL) Alfasigma S.p.A.

Italy (IT)

How to cite

APA:

Galli, M., Chatterjee, M., Grasso, M., Specchia, G., Magen, H., Einsele, H.,... Nagler, A. (2018). Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapy. Haematologica, 103(10), e469-e472. https://doi.org/10.3324/haematol.2017.182865

MLA:

Galli, Monica, et al. "Phase I study of the heparanase inhibitor roneparstat: An innovative approach for multiple myeloma therapy." Haematologica 103.10 (2018): e469-e472.

BibTeX: Download